Vascular disrupting agent drug classes differ in effects on the cytoskeleton

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Kim, Sujeong ^a   Peshkin, Leonid ^a   Mitchison, Timothy J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; COMBRETASTATIN A4; MITOFLAXONE; TUBULIN; VADIMEZAN; VASCULAR TARGETING AGENT;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; DEPOLYMERIZATION; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEUKOCYTE; MICROTUBULE; MITOSIS INHIBITION; PROTEIN LOCALIZATION; PROTEIN POLYMERIZATION; SIGNAL TRANSDUCTION; TUMOR NECROSIS; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAPILLARY PERMEABILITY; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICROTUBULES; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; STILBENES; XANTHONES;

EID: 84864182337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040177     Document Type: Article

References (31)

1. Eichhorn ME, Kleespies A, Angele MK, Jauch KW, Bruns CJ, (2007) Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg 392: 371-379.
2. Folkman J, (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
3. Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J, (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136: 261-276.
4. Shih T, Lindley C, (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28: 1779-1802.
5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, et al. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834.
6. Zwi LJ, Baguley BC, Gavin JB, Wilson WR, (1994) Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6: 79-85.
7. Cushman M, Nagarathnam D, Gopal D, Chakraborti AK, Lin CM, et al. (1991) Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J Med Chem 34: 2579-2588.
8. Plowman J, Narayanan VL, Dykes D, Szarvasi E, Briet P, et al. (1986) Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70: 631-635.
9. Baguley BC, (2003) Antivascular therapy of cancer: DMXAA. Lancet Oncol 4: 141-148.
10. Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, et al. (2011) Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 22: 2036-2041.
11. Head M, Jameson MB, (2010) The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Expert Opin Investig Drugs 19: 295-304.
12. Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, et al. (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29: 2965-2971.
13. Kanthou C, Tozer GM, (2002) The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99: 2060-2069.
14. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, et al. (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115: 2992-3006.
15. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, et al. (2001) Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21: 93-102.
16. Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, et al. (2007) The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med 204: 1559-1569.
17. Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, et al. (1999) Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59: 3304-3307.
18. Zhao L, Ching LM, Kestell P, Baguley BC, (2002) The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87: 465-470.
19. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, et al. (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer 86: 1937-1942.
20. Schwartz EL, (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15: 2594-2601.
21. Nam NH, (2003) Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Med Chem 10: 1697-1722.
22. Hamel E, (2003) Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. Cell Biochem Biophys 38: 1-22.
23. Panaro NJ, Popescu NC, Harris SR, Thorgeirsson UP, (1999) Flavone acetic acid induces a G2/M cell cycle arrest in mammary carcinoma cells. Br J Cancer 80: 1905-1911.
24. Mitchison TJ, (1992) Actin based motility on retraction fibers in mitotic PtK2 cells. Cell Motil Cytoskeleton 22: 135-151.
25. Jordan MA, Thrower D, Wilson L, (1992) Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci 102 (Pt 3): 401-416.
26. Orth JD, Tang Y, Shi J, Loy CT, Amendt C, et al. (2008) Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol Cancer Ther 7: 3480-3489.
27. Shi J, Orth JD, Mitchison T, (2008) Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 68: 3269-3276.
28. Tozer GM, Kanthou C, Baguley BC, (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435.
29. Wu Q, Quan H, Xu Y, Li Y, Hu Y, et al. (2012) p38 MAPK is required for the antitumor activity of the vascular-disrupting agent DMXAA. J Pharmacol Exp Ther.
30. Wang LC, Reddy CB, Baguley BC, Kestell P, Sutherland R, et al. (2004) Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochem Pharmacol 67: 937-945.
31. Belmont LD, Hyman AA, Sawin KE, Mitchison TJ, (1990) Real-time visualization of cell cycle-dependent changes in microtubule dynamics in cytoplasmic extracts. Cell 62: 579-589.